Pricing Log in Create free account
Friday 6 November 2026 Export XENE’s income statement to Excel — free account

Xenon Pharmaceuticals Inc.

XENE Healthcare Biotechnology

Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.

Revenue
+100.7%
EPS
−3.74%
Free cash flow
−48.6%

Quarter to June 2026, against a year earlier

39.00 1.32 +3.50%
Market cap
$3.7B
P/E
0.0×
Fwd P/E
−8.1×
Dividend yield
—
F-score
n/a
Altman Z
37.76
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Xenon Pharmaceuticals Inc. (XENE) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Xenon Pharmaceuticals Inc. (XENE) trades at a P/B ratio of 3.0×. Over the past ten years it has ranged from 0.6× (February 2015) to 24.5× (June 2018); the current reading is higher than 50% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 6.1× 95.30%
FY2022 3.1× 24.40%
FY2021 2.5× (22.59%)
FY2020 3.2× (19.57%)
FY2019 4.0× 180.05%
FY2017 1.4× (24.27%)
FY2016 1.9× 1.16%
FY2015 1.9× —

Quarterly newest first

Period P/B ratio Change
Mar 2025 3.8× 19.51%
Sep 2022 3.1× 44.25%
Jun 2022 2.2× (29.71%)
Mar 2022 3.1× 23.14%
22 more quarters

Against its own ten years

Low 0.6× High 24.5×
Ten-year median 3.0×
Current reading's percentile 47

P/B ratio against peers

Company P/B ratio
PBLS Parabilis Medicines, Inc. compare 0.8×
ACAD ACADIA Pharmaceuticals Inc. compare 2.6×
XENE Xenon Pharmaceuticals Inc. 3.0×
TNGX Tango Therapeutics, Inc. compare 3.1×
ABCL AbCellera Biologics Inc. compare 3.8×
RLAY Relay Therapeutics, Inc. compare 3.9×
IOVA Iovance Biotherapeutics, Inc. compare 4.3×
IRON Disc Medicine, Inc. compare 4.7×
VKTX Viking Therapeutics, Inc. compare 5.2×
Biotechnology industry median 2.0×
Healthcare sector median 2.3×
Market median 1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on XENE